Critical Limb Ischemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

CLI Pipeline Drugs Market Overview

Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet and hands. Symptoms include pain or numbness in feet or toes, sores, skin infections will not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality of life and increasing survival.

The CLI pipeline drugs market research report provides comprehensive information on the therapeutics under development for CLI, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for CLI and features dormant and discontinued projects.

CLI Pipeline Drugs Market Segmentation by Targets

Some of the targets of the CLI pipeline drugs market are Hepatocyte Growth Factor, E Selectin, Fibroblast Growth Factor 2, Prostaglandin E2 Receptor EP1 Subtype, Soluble Guanylate Cyclase, and Telomerase Reverse Transcriptase.

CLI Pipeline Drugs Market Analysis, by Targets

CLI Pipeline Drugs Market Analysis, by Targets

For more CLI pipeline drugs market target insights, download a free report sample

CLI Pipeline Drugs Market Segmentation by Mechanism of Actions

Some of the mechanisms of action of the CLI pipeline drugs market are Hepatocyte Growth Factor Activator, E Selectin Activator, Fibroblast Growth Factor 2 Activator, Prostaglandin E2 Receptor EP1 Subtype Agonist, Soluble Guanylate Cyclase Activator, and Telomerase Reverse Transcriptase Activator.

CLI Pipeline Drugs Market Analysis, by Mechanism of Actions

CLI Pipeline Drugs Market Analysis, by Mechanism of Actions

For more mechanism of action insights into the CLI pipeline drugs market, download a free report sample

CLI Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the CLI pipeline drugs market are intramuscular, intravenous, intraarterial, intraarticular, intracoronary, intrathecal, intravascular, and subcutaneous.

CLI Pipeline Drugs Market Analysis, by Routes of Administration

CLI Pipeline Drugs Market Analysis, by Routes of Administration

For more routes of administration insights into the CLI pipeline drugs market, download a free report sample

CLI Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the CLI pipeline drugs market are Cell Therapy, Gene Therapy, Biologic, Small Molecule, Gene-Modified Cell Therapy, Monoclonal Antibody, and Synthetic Peptide.

CLI Pipeline Drugs Market Analysis, by Molecule Types

CLI Pipeline Drugs Market Analysis, by Molecule Types

For more molecule type insights into the CLI pipeline drugs market, download a free report sample

Competitive Landscape

Some of the key companies in the CLI pipeline drugs market are Ambulero Inc, Caladrius Biosciences Inc, Cynata Therapeutics Ltd, Helixmith Co Ltd, ID Pharma Co Ltd, Ixaka Ltd, Reven Holdings Inc, Antidote Therapeutics Inc, Athersys Inc, and Constant Therapeutics LLC.

CLI Pipeline Drugs Market Analysis, by Companies

CLI Pipeline Drugs Market Analysis, by Companies

To know more about the CLI pipeline drugs market companies, download a free report sample

CLI Pipeline Drugs Market Report Overview

Key Targets Hepatocyte Growth Factor, E Selectin, Fibroblast Growth Factor 2, Prostaglandin E2 Receptor EP1 Subtype, Soluble Guanylate Cyclase, and Telomerase Reverse Transcriptase
Key Mechanism of Actions Hepatocyte Growth Factor Activator, E Selectin Activator, Fibroblast Growth Factor 2 Activator, Prostaglandin E2 Receptor EP1 Subtype Agonist, Soluble Guanylate Cyclase Activator, and Telomerase Reverse Transcriptase Activator
Key Routes of Administration Intramuscular, Intravenous, Intraarterial, Intraarticular, Intracoronary, Intrathecal, Intravascular, and Subcutaneous
Key Molecule Types Cell Therapy, Gene Therapy, Biologic, Small Molecule, Gene-Modified Cell Therapy, Monoclonal Antibody, and Synthetic Peptide
Key Companies Ambulero Inc, Caladrius Biosciences Inc, Cynata Therapeutics Ltd, Helixmith Co Ltd, ID Pharma Co Ltd, Ixaka Ltd, Reven Holdings Inc, Antidote Therapeutics Inc, Athersys Inc, and Constant Therapeutics LLC

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Critical limb ischemia (CLI).
  • Reviews of pipeline therapeutics for CLI by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Reviews of key companies involved in CLI therapeutics and enlists all their major and minor projects.
  • Evaluation of CLI therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Critical limb ischemia (CLI).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with the potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Critical limb ischemia (CLI).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding CLI pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Ambulero Inc
Antidote Therapeutics Inc
Athersys Inc
Caladrius Biosciences Inc
Constant Therapeutics LLC
Cynata Therapeutics Ltd
Gurus BioPharm Inc
Helixmith Co Ltd
Hemostemix Inc
ID Pharma Co Ltd
ImmuneCyte Inc
Ixaka Ltd
Kangstem Biotech Co Ltd
Libella Gene Therapeutics
New Beta Innovation Ltd
Orgenesis Inc
Pharmicell Co Ltd
Pluri Inc
Reven Holdings Inc
S.Biomedics Co Ltd
Taiwan Bio Therapeutics Co Ltd
Theratome Bio Inc
VESSL Therapeutics Ltd
Vivazome Therapeutics Pty Ltd
Yichang Humanwell Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Critical Limb Ischemia – Overview

Critical Limb Ischemia – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Critical Limb Ischemia – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Critical Limb Ischemia – Companies Involved in Therapeutics Development

Critical Limb Ischemia – Drug Profiles

Critical Limb Ischemia – Dormant Projects

Critical Limb Ischemia – Discontinued Products

Critical Limb Ischemia – Product Development Milestones

Featured News & Press Releases

May 10, 2022: Hemostemix announces its intellectual property is back home

Mar 24, 2022: Hemostemix announces settlement agreement

Sep 08, 2021: Ixaka announces positive interim Phase 3 clinical trial data for its lead cell therapy candidate REX-001

Jul 06, 2021: Hemostemix provides update of Phase II clinical trial, 9th Circuit Court Decision including Cost Award and its Annual General Meeting Results

Apr 23, 2021: Hemostemix announces completion of phase II clinical trial subject follow up & HMTXF Up-list

Mar 18, 2021: Hemostemix announces clinical trial update and contract with Globex data to encrypt its communications with regulatory authorities

Jan 28, 2021: Hemostemix announces HS 12 – 01 clinical trial completion of subjects’ follow-up visits at the end of march and warrants extented and repriced

Oct 26, 2020: Rexgenero announces positive outcome of independent data monitoring committee meeting for phase III trial for diabetic patients with critical limb-threatening ischaemia

Sep 09, 2020: Caladrius Biosciences announces registration of HONEDRA trademark and new patent in Japan

Jul 06, 2020: Aspire Health Science, announces release of ACP-01 midpoint analysis to Hemostemix

Apr 01, 2020: Cynata provides guidance on planned CLI clinical trial

Mar 03, 2020: Canadian patent issued for Cynata Therapeutics unique stem cell technology

Jan 26, 2020: Hemostemix provides corporate update and clarification

Jan 14, 2020: UK regulatory authority approves Cynata’s phase 2 clinical trial in critical limb ischaemia

Nov 25, 2019: Cynata files application to commence phase 2 clinical trial in critical limb ischaemia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Critical Limb Ischemia, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Critical Limb Ischemia – Dormant Projects, 2022

Critical Limb Ischemia – Dormant Projects, 2022 (Contd..1)

Critical Limb Ischemia – Dormant Projects, 2022 (Contd..2)

Critical Limb Ischemia – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Critical Limb Ischemia, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Critical Limb Ischemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Critical Limb Ischemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Critical Limb Ischemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Critical Limb Ischemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.